|Institutional Source||Beutler Lab|
|Synonyms||Gcdp, V1, 5033418D15Rik|
|Is this an essential gene?||Possibly non essential (E-score: 0.401)|
|Stock #||R5843 (G1)|
|Chromosomal Location||35508906-35539888 bp(-) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||C to T at 35512290 bp|
|Amino Acid Change||Aspartic acid to Asparagine at position 100 (D100N)|
|Ref Sequence||ENSEMBL: ENSMUSP00000031866 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000031866]|
|Predicted Effect||probably benign
AA Change: D100N
PolyPhen 2 Score 0.002 (Sensitivity: 0.99; Specificity: 0.30)
AA Change: D100N
|Meta Mutation Damage Score||0.1901|
|Coding Region Coverage||
|MGI Phenotype||FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The transcript produced from this gene is bi-cistronic and can encode both myotrophin and leucine zipper protein 6. The myotrophin protein is associated with cardiac hypertrophy, where it is involved in the conversion of NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers. This protein also has a potential function in cerebellar morphogenesis, and it may be involved in the differentiation of cerebellar neurons, particularly of granule cells. A cryptic ORF at the 3' end of this transcript uses a novel internal ribosome entry site and a non-AUG translation initiation codon to produce leucine zipper protein 6, a 6.4 kDa tumor antigen that is associated with myeloproliferative disease. [provided by RefSeq, Jul 2008]|
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Mtpn||
(F):5'- TCACCCTCTTAAAGTATTTAGCTGAAG -3'
(R):5'- CGGTTAAGTGAGCTCCAACTCT -3'
(F):5'- CTGAAGAAGCTGGCAGATAGAAAGTG -3'
(R):5'- TGAATCAGATGTAAGCTCTCAGC -3'